Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023

Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023

Blog Article

Abstract The treatment of proliferative diabetic retinopathy (PDR) has evolved significantly since the initial use of panretinal photocoagulation as a treatment in the 1950s.Vascular endothelial growth factor inhibitors have provided an effective alternative without the risk of peripheral vision loss.Despite this, the risk Essential Oil Roll-On of complications requiring surgical intervention in PDR remains high.Intravitreal bevacizumab has shown promise as a preoperative adjuvant to vitrectomy for PDR complications, albeit with a purported risk for tractional retinal detachment (TRD) progression in eyes with significant fibrous proliferation.Here we will discuss anti-VEGF agent use Studs in PDR and its role in surgical intervention for PDR complications including TRD.